Pharmacological Activation of Neuronal Voltage-Gated Kv7/KCNQ/M-Channels for Potential Therapy of Epilepsy and Pain
The DOI matches its Crossref record; 106 of the 107 references it cites were found in a registry or an index.
Abstract
Native M-current is a low-threshold, slowly activating potassium current that exerts an inhibitory control over neuronal excitability. The M-channel is primarily co-assembled by heterotetrameric Kv7.2/KCNQ2 and Kv7.3/KCNQ3 subunits that are specifically expressed in the brain and peripheral nociceptive and visceral sensory neurons in the spinal cord. Reduction of M-channel function leads to neuronal hyperexcitability that defines the fundamental mechanism of neurological disorders such as epilepsy and pain, indicating that pharmacological activation of Kv7/KCNQ/M-channels may serve the basis for the therapy. The well-known KCNQ opener retigabine (ezogabine or Potiga) was approved by FDA in 2011 as an anticonvulsant used for an adjunctive treatment of partial epilepsies. Unfortunately, retigabine was discontinued in 2017 due to its side effects of blue-colored appearance of the skin and eyes after prolonged intake. In addition, flupirtine, a structural derivative of retigabine and a centrally acting non-opioid analgesic, was also withdrawn in 2018 for liver toxicity. Fortunately, these side effects are compound-structures related and can be avoided. Thus, further identification and development of novel potent and selective Kv7 channel openers may lead to an effective therapy with improved safety window for anti-epilepsy and anti-nociception.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The Kv7 potassium channel enhancer QO-83, a small-molecule KCNQ/Kv7 channel opener, limits infarct volume, edema, and cognitive decline after ischemic injury while curbing microglial activation, pointing to attenuation of excitotoxic cascades that often follow stress or drug withdrawal [252,255,256,257].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [256]
In the citing paper
“Beyond mood, ezogabine reduces cortical and spinal motor neuron excitability in amyotrophic lateral sclerosis and decreases seizure frequency in refractory epilepsy, demonstrating target engagement in human hyperexcitable states and supporting its transdiagnostic potential to quiet unstable circuits [256,262,263].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [256]
In the citing paper
“Pan-selective Kv7 openers such as Lu AA41178, a brain-penetrant Kv7.2–Kv7.5 potassium channel activator, extend these findings, reducing depressive-like behavior while elevating seizure thresholds without major off-target liabilities, suggesting a favorable translatability profile for network stabilization [255,256].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [256]
Citations
Cites
Muscarinic suppression of a novel voltage-sensitive K+ current in a vertebrate neurone
Brown, D. A., & Adams, P. R. (1980) · Nature · doi:10.1038/283673a0 · Cited by 1,444
KCNQ2 and KCNQ3 Potassium Channel Subunits: Molecular Correlates of the M-Channel
Wang, H. (1998) · Science · doi:10.1126/science.282.5395.1890 · Cited by 1,294
A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns
Singh, N. A., Charlier, C., Stauffer, D., DuPont, B. R., Leach, R. J., Melis, R., Ronen, G. M., Bjerre, I., Quattlebaum, T., Murphy, J. V., et al. (1998) · Nature Genetics · doi:10.1038/ng0198-25 · Cited by 1,199
A Potassium Channel Mutation in Neonatal Human Epilepsy
Biervert, C., Schroeder, B. C., Kubisch, C., Berkovic, S. F., Propping, P., Jentsch, T. J., & Steinlein, O. K. (1998) · Science · doi:10.1126/science.279.5349.403 · Cited by 1,073
A pore mutation in a novel KQT-like potassium channel gene in an idiopathic epilepsy family
Charlier, C., Singh, N. A., Ryan, S. G., Lewis, T. B., Reus, B. E., Leach, R. J., & Leppert, M. (1998) · Nature Genetics · doi:10.1038/ng0198-53 · Cited by 937
Neyroud, N., Tesson, F., Denjoy, I., Leibovici, M., Donger, C., Barhanin, J., Fauré, S., Gary, F., Coumel, P., Petit, C., et al. (1997) · Nature Genetics · doi:10.1038/ng0297-186 · Cited by 891
Kubisch, C., Schroeder, B. C., Friedrich, T., Lütjohann, B., El-Amraoui, A., Marlin, S., Petit, C., & Jentsch, T. J. (1999) · Cell · doi:10.1016/s0092-8674(00)80556-5 · Cited by 867
Pathways modulating neural KCNQ/M (Kv7) potassium channels
Delmas, P., & Brown, D. A. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1785 · Cited by 686
Zhang, H., Craciun, L. C., Mirshahi, T., Rohács, T., Lopes, C. M. B., Jin, T., & Logothetis, D. E. (2003) · Neuron · doi:10.1016/s0896-6273(03)00125-9 · Cited by 523
Moderate loss of function of cyclic-AMP-modulated KCNQ2/KCNQ3 K+ channels causes epilepsy
Schroeder, B. C., Kubisch, C., Stein, V., & Jentsch, T. J. (1998) · Nature · doi:10.1038/25367 · Cited by 521
Cited by
Alles, S., & Smith, P. A. (2021) · Frontiers in Pain Research · doi:10.3389/fpain.2021.750583 · Cited by 87
“2 protein expression (69, 70) Mechanism of action yet to be”
BackgroundStructural insights into the lipid and ligand regulation of a human neuronal KCNQ channel
Zheng, Y. Y., Liu, H., Chen, Y., Dong, S., Wang, F., Wang, S., Li, G., Shu, Y., & Xu, F. (2021) · Neuron · doi:10.1016/j.neuron.2021.10.029 · Cited by 88
Ma, D., Zhong, L., Yan, Z., Yao, J., Zhang, Y., Ye, F., Huang, Y., Lai, D., Yang, W., Hou, P., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2207067119 · Cited by 61
Voltage-gated potassium channels and genetic epilepsy
Zheng, Y., & Chen, J. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1466075 · Cited by 40
Qiu, Q., Yang, M., Gong, D., Liang, H., & Chen, T. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-23-01766 · Cited by 39
Liu, X. (2022) · Journal of Inflammation Research · doi:10.2147/jir.s379093 · Cited by 31
“M-channel opener Flupirtine was used as an analgesic and withdrawn in 2018 for liver toxicity.(162) Both TNF-α and IL-β downregulate K channels in DRG neurons.”
MethodVoltage-gated potassium channels KCNQs: Structures, mechanisms, and modulations
Huang, Y., Ma, D., Yang, Z., Zhao, Y., & Guo, J. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.149218 · Cited by 24
Themistocleous, A. C., Baskozos, G., Blesneac, I., Comini, M., Mégy, K., Chong, S., Deevi, S. V. V., Ginsberg, L., Gosal, D. Y., Hadden, R. D. M., et al. (2023) · Brain Communications · doi:10.1093/braincomms/fcad037 · Cited by 24
The binding and mechanism of a positive allosteric modulator of Kv3 channels
Liang, Q., Chi, G., Cirqueira, L., Zhi, L., Marasco, A., Pilati, N., Gunthorpe, M. J., Alvaro, G. S., Large, C. H., Sauer, D. B., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46813-8 · Cited by 24
Zhan, D., Zhang, J., Su, S., Ren, X., Zhao, S., Zang, W., & Cao, J. (2023) · Neuroscience Bulletin · doi:10.1007/s12264-023-01139-1 · Cited by 14
“…evidence indicates that activation of the M channel is essential for the potential treatment of inflammatory pain [9, 27, 28], neuropathic pain [29–31], osteoarthritic pain [32, 33], bone cancer pain [26, 34], paclitaxel-induced peripheral neuropathy [35], chronic visceral pain [36], and…”
Sharples, S. A., Broadhead, M. J., Gray, J. A., & Miles, G. B. (2023) · The Journal of Physiology · doi:10.1113/jp285348 · Cited by 15
Intracellular zinc protects Kv7 K+ channels from Ca2+/calmodulin-mediated inhibition
Yang, X., Chen, D., Zhang, S., Shi, S., Zong, R. L., Gao, Y., Guan, B., Gamper, N. L., & Gao, H. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102819 · Cited by 13
“Conversely, M channel enhancers reduce excitability and were clinically used as anticonvulsants (retigabine) or analgesics (flupirtine), although these drugs are now discontinued because of side effects (13).”
BackgroundLuque, M. A., Morcuende, S., Torres, B., & Herrero, L. (2024) · The Journal of Physiology · doi:10.1113/jp285244 · Cited by 9
“Given these antecedents, efforts to develop Kv7/M channel openers have been devoted for therapy of epilepsy (Liu et al., 2021).”
Discovery of a novel KV7.2/7.3 channels agonist for the treatment of neuropathic pain
Qian, K., Zhou, J., Xiong, J., Wang, Q., Chen, L., Zhuang, T., Jin, J., Zhang, G., Hao, C., Huang, L., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116953 · Cited by 8
IDOR-1104-0086, a novel Kv7 channel activator with antiseizure effects in rodents
Kessler, M. S., Mühlemann, A., Mis, M. A., Siegrist, R., Seeland, S., Deymier, C., Mathieu, C.-A., Roellinger, H., Atanasova, T., Roch, C., et al. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110658 · Cited by 6
Zhuang, X.-F., Liu, Y., Yang, Z.-H., Gao, Q. F., Wang, L., Ju, C., & Wang, K. (2022) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.122.001328 · Cited by 6
“SCR2682 is a structurally distinct lead compound with better potency and efficacy in comparison with retigabine (Zhang et al., 2019; Liu et al., 2021).”
BackgroundSelf-citationPharmacology of Potassium Channels
(2021) · Handbook of experimental pharmacology · doi:10.1007/978-3-030-84052-5 · Cited by 7
Cooper, B. Y., Nutter, T. J., Flunker, L. D., & Bowers, C. M. (2022) · NeuroToxicology · doi:10.1016/j.neuro.2022.10.003 · Cited by 3
Shi, H., Li, Q., Hu, F., Liu, Y., & Wang, K. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03291-w · Cited by 2
Self-citationYang, B., Liu, H., Zhao, W., Ma, J.-R., Kang, Z.-S., Zhang, Y., Gu, Y.-L., Li, X.-K., Mao, Z.-W., Cao, R.-F., et al. (2025) · Acta Pharmacologica Sinica · doi:10.1038/s41401-025-01627-2 · Cited by 3
“3 currents was 8.8 ± 1.6 μ mol· L − 1 , whereas fl upirtine, used as an analgesic in the clinic, has an EC 50 value of 4.6 μ mol· L − 1 [67].”
InfluentialCircuit-based intervention corrects excessive dentate gyrus output in the fragile X mouse model
Deng, P., Kumar, A., Cavalli, V., & Klyachko, V. A. (2023) · eLife · doi:10.7554/elife.92563 · Cited by 7
Sun, H., & Undem, B. J. (2024) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.123.001959 · Cited by 2
“Retigabine was later withdrawn from the market due to its compound structure-related toxicity (retinal pigmentation and skin discoloration)(Liu et al., 2021), as well as other side effects that are at least partially related to its poor selectivity for distinct K V 7 subunits.”
BackgroundStructural basis for heteromeric assembly and subthreshold activation of human M-channel
Wang, Y., Yang, H. L., Qu, Y., Li, J., Li, X., Hou, W., Wu, K., Xie, G., Wang, X., Ye, Y., et al. (2026) · Vita · doi:10.15302/vita.2026.05.0032 · Cited by 2
Yang, S. Y., Yun, T., Lee, Y., Jeon, J. H., Kim, S., Lim, E. Y., Park, J., Kim, Y. G., Jung, J., Woo, J.-N., et al. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02748-8 · Cited by 1
“27,28 Twik-1, also known as Kcnk1, K2P1, or K2P1.”
Şaylan, A., Türel, C. A., Türel, İ., Çetinkaya, A., & Torun, İ. E. (2023) · Experimental Biomedical Research · doi:10.30714/j-ebr.2023.171 · Cited by 1
Circuit-based intervention corrects excessive dentate gyrus output in the Fragile X mouse modelPreprint
Deng, P., Kumar, A., Cavalli, V., & Klyachko, V. A. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.09.27.559792 · Cited by 1
“…that plays key roles in regulating neuronal excitability throughout the brain ( Brown and Passmore, 2009 ; Delmas and Brown, 2005 ; Jones et al., 2021 ; Liu et al., 2021 ), including hippocampal neurons ( Gu et al., 2005 ; Incontro et al., 2021 ; Martinello et al., 2015 ; Peters et al., 2005 ).”
Circuit-based intervention corrects excessive dentate gyrus output in the Fragile X mouse modelPreprint
Deng, P., Kumar, A., Cavalli, V., & Klyachko, V. A. (2024) · eLife · doi:10.7554/elife.92563.2 · Cited by 1
Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery
Tanaka, M. (2026) · Biomedicines · doi:10.3390/biomedicines14061265
Circuit-based intervention corrects excessive dentate gyrus output in the Fragile X mouse modelPreprint
Deng, P., Kumar, A., Cavalli, V., & Klyachko, V. A. (2023) · eLife · doi:10.7554/elife.92563.1
Therapeutic Targeting of Potassium Channels
Gamper, N. L., Huang, D., Qi, J., Dong, L., & Zhang, H. (2024) · Springer eBooks · doi:10.1007/978-3-031-52197-3_5 · Cited by 1
Arichi, S., Eto, K., Ogata, M., Sasaki‐Hamada, S., & Ishibashi, H. (2025) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b24-00498
Elucidation of the zinc binding site in KCNQ channels
Zhang, S., Yang, X., Yang, M., Cao, Y., Shi, S., Gamper, N. L., & Gao, H. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70177
“(Du et al., 2018; Jones et al., 2021; Liu et al., 2021; Perucca & Taglialatela, 2025).”
InfluentialXiang, W., Qu, Y., Kong, X., Yang, Y., Hu, F., Wang, K., Wei, N., & Qiao, Z. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.110099 · Cited by 1
Self-citationBindingDB (2026) · UC San Diego · doi:10.7270/q2nv9q41
Metadata
- Authors
- Liu, Y., Bian, X., & Wang, K.
- Affiliations
- Qingdao University (CN)
- Peking University (CN)
- Corresponding author
- Wang, KeWei
- ORCID
- Venue
- Handbook of Experimental Pharmacology
- Publisher
- Springer International Publishing
- Published
- 2021
- Volume
- 267
- Pages
- 231-251
- ISSN
- 0171-2004 (ISSN-L)
- 1865-0325
- OpenAlex
- W3142768988
- Cited by
- 36
- References
- 107
- Citations by year
- 2026: 5 · 2025: 5 · 2024: 9 · 2023: 9 · 2022: 5 · 2021: 3
- FWCI
- 10.93
- Type
- book chapter
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Handbook of experimental pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ion channel regulation and function
- Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Keywords
- Kv7 channels, KCNQ channels, M-current, retigabine, flupirtine, epilepsy, pain, nociception, neuronal hyperexcitability, antiepileptic drugs, adverse drug reactions
- MeSH terms
- Anticonvulsants, Epilepsy, Humans, Neurons, Pain, KCNQ Potassium Channels
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.